Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tassilo L A Wachsmann

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Nature Biotechnology|October 8, 2025
Durable epigenetic silencing with a TALE-based editorTassilo L A Wachsmann, Lei S Qi
Trends in Cancer|August 29, 2025
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptomeTassilo L A Wachsmann, Lei S Qi
Blood Advances|August 11, 2023
Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myelomaTassilo L A Wachsmann, Miranda H Meeuwsen, Dennis F G Remst, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasionLaura T Morton, Tassilo L A Wachsmann, Miranda H Meeuwsen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 1, 2025
CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cellsTassilo L A Wachsmann, Teuntje Poortvliet, Miranda H Meeuwsen, et al.
Oncoimmunology|February 7, 2022
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposureTassilo L A Wachsmann, Anne K Wouters, Dennis F G Remst, et al.
Molecular Therapy. Oncology|August 12, 2025
DNA-demethylation by DAC induces <i>MAGE</i> expression and MAGE-specific T cell reactivity against tumors but also healthy cell subsetsMarije A J de Rooij, Miranda H Meeuwsen, Anne K Wouters, et al.
Molecular Therapy. Nucleic Acids|May 15, 2024
CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancerAshwathi Puravankara Menon, Helena Villanueva, Daniel Meraviglia-Crivelli, et al.
Journal for Immunotherapy of Cancer|September 26, 2024
Targeting epigenetic regulation and post-translational modification with 5-Aza-2' deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapyJessie S Kroonen, Anne K Wouters, Ilona J de Graaf, et al.
Molecular Therapy Oncolytics|November 3, 2023
Erratum: A library of cancer testis specific T cell receptors for T cell receptor gene therapyMarije A J de Rooij, Dennis F G Remst, Dirk M van der Steen, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Nature Biotechnology|October 8, 2025
Durable epigenetic silencing with a TALE-based editorTassilo L A Wachsmann, Lei S Qi
Trends in Cancer|August 29, 2025
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptomeTassilo L A Wachsmann, Lei S Qi
Blood Advances|August 11, 2023
Combining BCMA-targeting CAR T cells with TCR-engineered T-cell therapy to prevent immune escape of multiple myelomaTassilo L A Wachsmann, Miranda H Meeuwsen, Dennis F G Remst, et al.
Journal for Immunotherapy of Cancer|March 15, 2022
T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasionLaura T Morton, Tassilo L A Wachsmann, Miranda H Meeuwsen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|March 1, 2025
CAR-mediated target recognition limits TCR-mediated target recognition of TCR- and CAR-dual-receptor-edited T cellsTassilo L A Wachsmann, Teuntje Poortvliet, Miranda H Meeuwsen, et al.
Oncoimmunology|February 7, 2022
Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposureTassilo L A Wachsmann, Anne K Wouters, Dennis F G Remst, et al.
Molecular Therapy. Oncology|August 12, 2025
DNA-demethylation by DAC induces <i>MAGE</i> expression and MAGE-specific T cell reactivity against tumors but also healthy cell subsetsMarije A J de Rooij, Miranda H Meeuwsen, Anne K Wouters, et al.
Molecular Therapy. Nucleic Acids|May 15, 2024
CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancerAshwathi Puravankara Menon, Helena Villanueva, Daniel Meraviglia-Crivelli, et al.
Journal for Immunotherapy of Cancer|September 26, 2024
Targeting epigenetic regulation and post-translational modification with 5-Aza-2' deoxycytidine and SUMO E1 inhibition augments T-cell receptor therapyJessie S Kroonen, Anne K Wouters, Ilona J de Graaf, et al.
Molecular Therapy Oncolytics|November 3, 2023
Erratum: A library of cancer testis specific T cell receptors for T cell receptor gene therapyMarije A J de Rooij, Dennis F G Remst, Dirk M van der Steen, et al.
Pageof 2